Neximmune Financials

We recommend to make use of Neximmune fundamental analysis to find out if markets are presently mispricing the entity. Strictly speaking this technique allows you to check out available financial ratios of Neximmune as well as the relationship between them. We have analyzed and interpolated twenty-eight available fundamentals for Neximmune, which can be compared to its peers in the industry.
  

Neximmune Stock Summary

Neximmune competes with ZyVersa Therapeutics, Palisade Bio, Unicycive Therapeutics, Immix Biopharma, and Transcode Therapeutics. NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland. Neximmune operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 74 people.
Specialization
Healthcare, Biotechnology
InstrumentUSA Pink Sheet View All
ExchangePINK Exchange
ISINUS65344D1090
CUSIP65344D109 65344D208
LocationMaryland; U.S.A
Business Address9119 Gaither Road,
SectorBiotechnology
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.neximmune.com
Phone301 825 9810
CurrencyUSD - US Dollar

Neximmune Key Financial Ratios

Neximmune's financial ratios allow both analysts and investors to convert raw data from Neximmune's financial statements into concise, actionable information that can be used to evaluate the performance of Neximmune over time and compare it to other companies across industries.

Neximmune Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Neximmune's current stock value. Our valuation model uses many indicators to compare Neximmune value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Neximmune competition to find correlations between indicators driving Neximmune's intrinsic value. More Info.
Neximmune is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Neximmune by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Neximmune's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.
You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.

Other Consideration for investing in Neximmune Pink Sheet

If you are still planning to invest in Neximmune check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Neximmune's history and understand the potential risks before investing.
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Money Managers
Screen money managers from public funds and ETFs managed around the world
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios